FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical dosage form for treating cardiovascular diseases and introduced once a day, containing a combination of fixed doses of metoprolol or its pharmaceutically acceptable salt in the sustained-release form, amlodipine, or valsartan, or olmesartan, or lisinopril, or enalapril, or their pharmaceutically acceptable salts, and one or more speed-control polymeric excipients containing cellulose polymers or their derivatives, and acrylic acid polymers or their derivatives, which form two layers on metoprolol or their pharmaceutically acceptable salt,wherein the dosage form possesses such a solution profile that less than 6% of metoprolol or its pharmaceutically acceptable salt releases for 1 hour.
EFFECT: invention provides min 10% improved blood pressure after 3 months of treatment.
20 cl, 10 ex, 18 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
| COMBINATION OF DIPEPTIDILPEPTIDASE IV (DPP IV) INHIBITOR AND CARDIOVASCULAR SUBSTANCE | 2003 |
|
RU2336876C2 |
| MEDICINAL AGENT FOR TREATMENT OF HYPERTENSION OR HIGH BLOOD PRESSURE | 2010 |
|
RU2539382C2 |
| HYPOTENSIVE COMBINATION OF VALSARTAN AND CALCIUM CANAL BLOCKERS | 1999 |
|
RU2450813C2 |
| HYPOTENSIVE COMBINATION OF VALSARTAN AND CALCIUM CHANNEL BLOCKING AGENT | 1999 |
|
RU2243768C2 |
| APPLICATION OF ORGANIC COMPOUNDS | 2005 |
|
RU2426532C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| SYNERGETIC COMBINATIONS CONTAINING RENIN INHIBITOR AND INTENDED FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2006 |
|
RU2346703C2 |
| COMPOSITIONS FOR TREATING HYPERTENSION | 2019 |
|
RU2828226C2 |
| COMBINATION OF ORGANIC COMPOUNDS | 2003 |
|
RU2324482C2 |
